314 related articles for article (PubMed ID: 36081610)
1. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
Downton T; Zhou F; Segara D; Jeselsohn R; Lim E
Drug Des Devel Ther; 2022; 16():2933-2948. PubMed ID: 36081610
[TBL] [Abstract][Full Text] [Related]
2. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
3. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.
Neupane N; Bawek S; Gurusinghe S; Ghaffary EM; Mirmosayyeb O; Thapa S; Falkson C; O'Regan R; Dhakal A
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339371
[TBL] [Abstract][Full Text] [Related]
4. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.
Guglielmi G; Del Re M; Gol LS; Bengala C; Danesi R; Fogli S
Eur J Pharmacol; 2024 Apr; 969():176424. PubMed ID: 38402929
[TBL] [Abstract][Full Text] [Related]
6. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
7. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Hernando C; Ortega-Morillo B; Tapia M; Moragón S; Martínez MT; Eroles P; Garrido-Cano I; Adam-Artigues A; Lluch A; Bermejo B; Cejalvo JM
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360578
[TBL] [Abstract][Full Text] [Related]
8. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Scott JS; Barlaam B
Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
13. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
Chen YC; Yu J; Metcalfe C; De Bruyn T; Gelzleichter T; Malhi V; Perez-Moreno PD; Wang X
Expert Opin Investig Drugs; 2022 Jun; 31(6):515-529. PubMed ID: 34694932
[TBL] [Abstract][Full Text] [Related]
14. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
17. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
18. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
19. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Lloyd MR; Wander SA; Hamilton E; Razavi P; Bardia A
Ther Adv Med Oncol; 2022; 14():17588359221113694. PubMed ID: 35923930
[TBL] [Abstract][Full Text] [Related]
20. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
